We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Cencora (COR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Cencora is one of 995 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Cencora is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for COR's full-year earnings has moved 2.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, COR has moved about 29.6% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 5.3% on average. As we can see, Cencora is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Catalyst Pharmaceutical (CPRX - Free Report) . The stock has returned 19.6% year-to-date.
The consensus estimate for Catalyst Pharmaceutical's current year EPS has increased 2.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Cencora belongs to the Medical Services industry, a group that includes 58 individual stocks and currently sits at #68 in the Zacks Industry Rank. Stocks in this group have lost about 3.9% so far this year, so COR is performing better this group in terms of year-to-date returns.
Catalyst Pharmaceutical, however, belongs to the Medical - Drugs industry. Currently, this 161-stock industry is ranked #55. The industry has moved -1.8% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Cencora and Catalyst Pharmaceutical as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Cencora (COR - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Cencora is one of 995 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Cencora is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for COR's full-year earnings has moved 2.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, COR has moved about 29.6% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 5.3% on average. As we can see, Cencora is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Catalyst Pharmaceutical (CPRX - Free Report) . The stock has returned 19.6% year-to-date.
The consensus estimate for Catalyst Pharmaceutical's current year EPS has increased 2.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Cencora belongs to the Medical Services industry, a group that includes 58 individual stocks and currently sits at #68 in the Zacks Industry Rank. Stocks in this group have lost about 3.9% so far this year, so COR is performing better this group in terms of year-to-date returns.
Catalyst Pharmaceutical, however, belongs to the Medical - Drugs industry. Currently, this 161-stock industry is ranked #55. The industry has moved -1.8% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Cencora and Catalyst Pharmaceutical as they attempt to continue their solid performance.